Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients

Advances in Therapy

Volumn 29, Issue 7, 2012, Pages 635-644

  Mori, Hiroko ^a   Okada, Yosuke ^a   Arao, Tadashi ^a   Nishida, Keiko ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Diabetes mellitus; Glucose metabolism; High dose telmisartan; Highmolecular weight adiponectin; Insulin resistance; Lipid profile

Indexed keywords

ADIPONECTIN; AMLODIPINE; GLUCOSE; LIPID; TELMISARTAN;

AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EDEMA; FEMALE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; WEIGHT GAIN;

ADIPOCYTES; ADIPONECTIN; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MIDDLE AGED; PPAR GAMMA; TRIGLYCERIDES;

EID: 84866553780     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0032-x     Document Type: Article

References (24)

1. Benson SC, Pershadsingh HA, Ho CI, et al Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma-modulating activity Hypertension 2004;43:993-1002.
2. Schupp M, Janke J, Clasen R, Unger T, Kintscher U Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity Circulation 2004; 109:2054-7.
3. Schupp M, Clemenz M, Gineste R, et al Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity Diabetes 2005;54:3442-52.
4. Mori Y, Itoh Y, Tajima N Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity Am J Hypertens 2007;20:431-6.
5. Fujimoto M, Masuzaki H, Tanaka T, et al An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes FEBS Lett 2004;576:492-7.
6. Smith DH, Matzek KM, Kempthorne-Rawson J Dose response and safety of telmisartan in patients with mild to moderate hypertension J Clin Pharmacol 2000;40:1380-90.
7. Pershadsingh HA, Kurtz TW Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease Diabetes Care 2004;27:1015.
8. Fogari R, Zoppi A, Ferrari I, et al Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients Horm Metab Res 2009;41:893-8.
9. Lida M, Ueda K, Okayama A, et al.; NIPPON DATA 80 Research Group Impact of elevated blood pressure on mortality from all causes, cardiovascular disease, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese -Nippon data 80 J Hum Hypertens 2003; 17:851-7.
10. Blüher M, Brennan AM, Kelesidis T, et al Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays Diabetes Care 2007;30:280-5.
11. Seino Y, Nanjo K, Tajima N, et al.; Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus Report of the Committee on the classification and diagnostic criteria of diabetes mellitus J Diabetes Invest 2010; 1:212-28.
12. Kumada M, Kihara S, Sumitsuji S, et al.; Osaka CAD Study Group Coronary artery disease Association of hypoadiponectinemia with coronary artery disease in men Arterioscler Thromb Vasc Biol 2003;23:85-9.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 1985;28:412-9.
14. Teramoto T, Sasaki J, Ueshima H, et al.; Japan Atherosclerosis Society Committee for Epidemiology and Clinical Management of Atherosclerosis Diagnostic criteria for dyslipidemia Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese J Atheroscler Thromb 2007;14:155-8.
15. Shimabukuro M, Tanaka H, Shimabukuro T Effects of telmisartan on fat distribution in individuals with the metabolic syndrome J Hypertens 2007;25:841-8.
16. Ishii N, Matsumura T, Kinoshita H, et al Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 2010;30:1598-605.
17. Yamada S, Ano N, Toda K, et al Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro Hypertens Res 2008;31:601-6.
18. Shiuchi T, Iwai M, Li HS, et al Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice Hypertension 2004;43:1003-10.
19. Furuhashi M, Ura N, Takizawa H, et al Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity J Hypertens 2004;22:1977-82.
20. Janke J, Endeli S, Gorzelniak K, Luft FC, Sharma AM Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors Diabetes 2002;51:1699-1707.
21. Ausk KJ, Boyko EJ, Ioannou GM Insulin resistance predicts mortality in nondiabetic individuals in the U.S Diabetes Care 2010;33:1179-85.
22. Mudaliar S, Chang AR, Henry RR Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications Endocr Pract 2003;9:406-16.
23. White M, Racine N, Ducharme A, de Champlain J Therapeutic potential of angiotensin II receptor antagonists Expert Opin Investig Drugs 2001;10:1687-701.
24. Wakino S, Law RE, Hsueh WA Vascular protective effects by activation of nuclear receptor PPAR gamma J Diabetes Complications 2002;16:46-9.